March 27 (Reuters) - Aurinia Pharmaceuticals Inc AUP.TO :
* Aurinia Pharmaceuticals-announces 48-week results from "Aurinia early urinary protein reduction predicts response study" of voclosporin for treatment of lupus nephritis
* Aurinia Pharmaceuticals Inc says study successfully achieved primary objective - SEC filing
* Aurinia Pharmaceuticals says no new safety signals were observed with use of voclosporin in ln patients; voclosporin was well-tolerated Source text: Further company coverage: AUP.TO